STOCK TITAN
  1. Home
  2. News
  3. ALPMY

Astellas Pharma Inc. - ALPMY STOCK NEWS

Welcome to our dedicated news page for Astellas Pharma (Ticker: ALPMY), a resource for investors and traders seeking the latest updates and insights on Astellas Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Astellas Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Astellas Pharma's position in the market.

News
Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy
Rhea-AI Summary
Astellas Pharma Inc. (TSE: 4503) will present 24-week results from the Phase 3b DAYLIGHT clinical trial examining the efficacy and safety of fezolinetant, an investigational oral, nonhormonal compound for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause in women unsuitable for hormone therapy. The study of over 450 women met all primary and secondary endpoints at 24 weeks, demonstrating statistically significant reductions in the frequency and severity of VMS, as well as patient-reported sleep disturbance. Treatment-emergent adverse events were reported by 65% of patients in the fezolinetant group compared to 61% in the placebo group.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
none
-
News
Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting
Rhea-AI Summary
PFE and Astellas Pharma Inc. (4503) announced that the FDA approved a supplemental New Drug Application for XTANDI, making it the first and only androgen receptor signaling inhibitor approved for nonmetastatic castration-sensitive prostate cancer treatment with or without a GnRH analog therapy. This approval follows expedited development and review programs based on results from the Phase 3 EMBARK trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.2%
Tags
none
-
News
University of Tsukuba and Astellas Confirm a Strategic Partnership
Rhea-AI Summary
Astellas Pharma Inc. (TSE: 4503) and University of Tsukuba announced a strategic partnership to accelerate the digitalization of drug discovery research and the development of the life science ecosystem in Tsukuba and Kashiwa-no-ha. The partnership aims to promote innovative drug discovery research using AI and digital technologies and create new drug discovery startups. This agreement will facilitate industry-academia collaboration, utilization of research equipment and data, and the establishment of an office for the Tsukuba Digital-Bio International Center at Astellas' SakuLab™-Tsukuba. The collaboration is expected to turbocharge the development of pioneering healthcare solutions in the life science ecosystem.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
partnership
News
Astellas to Acquire Propella Therapeutics
Rhea-AI Summary
Astellas Pharma Inc. to Acquire PRL-02, a Prostate Cancer Treatment Program Developed by Propella Therapeutics
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
acquisition
-
News
Astellas Announces Data from ASPIRO Study in X-linked Myotubular Myopathy Published in The Lancet Neurology
Rhea-AI Summary
Astellas Pharma Inc. (TSE: 4503) reported preliminary data analysis from the ASPIRO trial, published in The Lancet Neurology, showcasing the safety and efficacy of investigational AT132 for pediatric patients with X-linked myotubular myopathy (XLMTM). The data revealed improvements in ventilator dependence and motor milestones, along with identified liver health issues. The study included 24 boys with XLMTM, showing significant reduction in ventilator support and achievement of major motor milestones post-gene therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
none
-
News
IZERVAY™ (avacincaptad pegol intravitreal solution) Monthly or Every Other Month Reduced Geographic Atrophy Lesion Growth Through 2 Years
Rhea-AI Summary
Astellas Pharma Inc. announced positive results from the GATHER2 Phase 3 clinical trial for IZERVAY, demonstrating its effectiveness in reducing the rate of geographic atrophy (GA) lesion growth in patients with age-related macular degeneration (AMD). The treatment effect of IZERVAY more than doubled over 2 years compared to 1 year. The safety profile of IZERVAY was consistent with year 1, with no cases of ischemic optic neuropathy or retinal vasculitis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Astellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023
Rhea-AI Summary
Astellas Pharma to present new research results at ESMO Congress 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.61%
Tags
none
-
News
Astellas Receives Positive CHMP Opinion for VEOZA™ (fezolinetant)
Rhea-AI Summary
Astellas Pharma receives positive opinion from CHMP for fezolinetant as a treatment for vasomotor symptoms associated with menopause.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.34%
Tags
none
-
News
Astellas, BioLabs and Mitsui Fudosan Announce a Collaboration to Enhance the Life Science Ecosystems in Tsukuba and Kashiwa-no-ha, Japan
Rhea-AI Summary
Astellas Pharma, BioLabs Global, and Mitsui Fudosan have agreed to enhance the life science ecosystem in Tsukuba and Kashiwa-no-ha, Japan by partnering to advance SakuLabTM-Tsukuba, an open innovation hub. Astellas will prepare experimental facilities for SakuLabTM-Tsukuba in its Tsukuba Research Center and provide networking opportunities for residents and researchers. The impact of this agreement has already been reflected in Astellas' financial forecast for the current fiscal year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
none
News
Two-time Emmy® Award-Winning Actor, Eric Stonestreet, Partners with Iveric Bio to Raise Awareness of Geographic Atrophy (GA)
Rhea-AI Summary
Iveric Bio partners with Eric Stonestreet to raise awareness about geographic atrophy (GA), a form of age-related macular degeneration (AMD) that causes irreversible vision loss. GA currently affects approximately 1.5 million people in the United States. The campaign aims to raise awareness of potential signs and symptoms of GA and encourages individuals to talk to their eye care professional about how to monitor for the disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.48%
Tags
partnership
Stock ALPMY logo
Astellas Pharma Inc.

OTC:ALPMY

ALPMY Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

ALPMY Stock Data

16.87B
1.79B
0%
Medicinal and Botanical Manufacturing
Manufacturing
Link
Japan
Chuo Ku